|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture显示文摘AIM: To determine the safety and effectiveness of transarterial embolization ablation (TEA) of hepatocellular carcinoma (HCC) with a lipiodol-ethanol mixture. METHODS: Between January 1 and December 31, 2009, 15 patients with HCC (13 men/two women, aged 38-75 years) accepted TEA treatment and were enrolled in this study, including five newly diagnosed patients and 10 with refractory disease. Two months after TEA, angiography and contrast computed tomography (CT) were performed, and responses were assessed using a modified version of Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). The follow-up period was to June 30, 2010. RESULTS: Every new case was treated once. Angiography was performed immediately after TEA, and showed that the tumor-feeding vessels were completely embolized and that lipiodol was densely deposited inside tumors. Two months after treatment, contrast CT showed no enhanced lesions. Alpha fetoprotein levels returned to normal in four patients and markedly decreased in another. mean ± SD survival after treatment was 10.8 ± 4.5 mo. All five patients survived during the follow-up period. Ten patients with refractory disease were treated a total of 14 times. Angiography immediately after TEA showed that blood flow to the tumors was obviously decreased in all cases, and contrast CT showed obvious depositions of lipiodol. Two months after treatment, the tumors had shrunk (6/10) or were stable (3/10). One had progressed after 2 mo and died of tumor rupture 3 mo after TEA. mean ± SD survival after treatment was 8.6 ± 4.3 mo; two patients survived during the follow-up period. Adverse effects included reversible hepatic decompensation, upper abdominal pain, and fever. CONCLUSION: TEA is an effective therapy for patients with HCC and might be more effective than transcather arterial chemoembolization for treating refractory disease. | Yang-Kui Gu, Rong-Guang Luo, Jin-Hua Huang, Qi-Jiao Si Tu, Xiao-Xia Li, Fei Gao,State Key Laboratory of Oncology in Southern China,Department of Medical Imaging and Interventional Radiology,Cancer Center,Sun Yat-sen University,Guangzhou510060,Guangdong Province,China Department of Medical Imaging and Interventional Radiology, the First Affiliated Hospital of Nan-Chang University, 17 Yongwaizheng Street, Nanchang 330006, Jiangxi Province, China | 2010 | World Journal of Gastroenterology2010，16，45： | 9 |
| 2 | 经肝动脉碘化油—无水乙醇混合剂栓塞消融术治疗中晚期肝癌的研究进展显示文摘原发性肝癌是最常见的消化系统恶性肿瘤之一,大多数患者确诊时已处于中晚期,失去外科手术的最佳时机。不能手术切除的中晚期肝癌患者生存期为3~6个月。目前,介入治疗是不可切除中晚期肝癌的主要治疗方法,其中经肝动脉灌注化疗栓塞术(TACE)被公认为是肝癌非手术切除的首选方法。但近年研究发现,其近期疗效显著,远期疗效并不理想。为了提高晚期肝癌患者的远期疗效,有学者将碘化油与无水乙醇混合成乳剂后经肝动脉注入治疗肝癌,取得了较好的效果。 | 钱亭 陈茂振 尹化斌 | 2013 | 山东医药2013，53，21： | 8 |
| 3 | 经肝动脉碘化油/无水乙醇混合剂栓塞消融术治疗兔VX_2肝癌的实验研究显示文摘目的通过比较不同容积比例的碘化油-无水乙醇混合剂(Lipiodol-ethanol mixture,LEM)治疗兔VX2肝癌模型的效果,确定LEM的最佳容积比例。方法将18只新西兰白兔按碘化油∶无水乙醇容积比例3∶1(A)、2∶1(B)、1∶1(C)、1∶2(D)、1∶3(E)、1∶4(F)分为6组,每组3只。1周后取肿瘤组织行病理学检查,观察肿瘤生长率,肿瘤微血管密度,肿瘤细胞凋亡指数(apoptosis index,AI)及肿瘤边缘肝组织损伤情况。结果 A、E、F 3组肿瘤体积增大,A组肿瘤生长率明显高于其他5组,差异有统计学意义(P<0.05),B、C、D 3组肿瘤体积缩小,但与肿瘤体积增大的E、F组比较,差异无统计学意义(P>0.05)。不同容积比例LEM中,无水乙醇比例与肿瘤微血管密度呈负相关(R2=0.840,F=89.432,P<0.001)。A组肿瘤AI明显低于C、D、E、F组(P<0.05),A、B组间差异无统计学意义(P>0.05)。B组与C、F组间差异有统计学意义(P<0.05),其他各组间差异无统计学意义(P>0.05)。A、B组肿瘤周围肝组织损伤明显低于其他各组(P<0.05)。结论从安全性方面考虑,LEM的最佳容积比例为2∶1。若能做到超选择插管至肿瘤供血动脉,严密透视监视下注射,适当提高无水乙醇比例,疗效更佳。 | 钱亭 陈茂振 高峰 尹化斌 | 2014 | 介入放射学杂志2014，23，8： | 7 |
| 4 | 无水乙醇碘油混合液栓塞治疗肾血管平滑肌脂肪瘤的疗效分析显示文摘目的 探讨无水乙醇碘油混合液介入栓塞治疗肾血管平滑肌脂肪瘤的价值。方法 回顾性分析我院采用无水乙醇碘油混合液栓塞治疗肾血管平滑肌脂肪瘤患者24例的资料,分析介入手术成功率,术后症状缓解、术后并发症及栓塞前后瘤体大小情况。结果 24例患者共30个病灶,介入栓塞治疗29个病灶,另1个病灶较小,择期处理,介入栓塞手术成功率100%。患者腰部疼痛、血尿症状术后均逐渐减轻、消失;患者栓塞术后出现不同程度的栓塞后综合征,其中发热12例(12/24,50%)、腹痛腹胀10例(10/24,41.67%)、恶心呕吐10例(10/24,41.67%),无严重并发症发生。随访6~12个月,瘤体最大径术前为(8.13±3.51)cm,术后为(5.29±2.18)cm,差异有统计学意义(P〈0.05)。结论 无水乙醇碘油混合液介入栓塞治疗肾血管平滑肌脂肪瘤疗效确切,安全有效,创伤小,值得临床推广应用。 | 宿敬存 姜永能 赵卫 胡继红 王滔 | 2016 | 中国介入影像与治疗学2016，13，12： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员